| Literature DB >> 27906043 |
Xiaohong Wang1, Chengfeng Xu1, Yitong Hua1, Leitao Sun2, Kai Cheng1, Zhongming Jia1, Yong Han1, Jianli Dong1, Yuzhen Cui1, Zhenlin Yang3.
Abstract
BACKGROUND: Release of exosomes have been shown to play critical roles in drug resistance by delivering cargo. Targeting the transfer of exosomes from resistant cells to sensitive cells may be an approach to overcome some cases of drug resistance.Entities:
Keywords: Breast cancer; Chemoresistance; Exosome; Psoralen
Mesh:
Substances:
Year: 2016 PMID: 27906043 PMCID: PMC5131502 DOI: 10.1186/s13046-016-0468-y
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
List of primers used for candidate genes
| Gene name | Forward primer (5'to 3') | Reverse primer (5'to 3') | prodSize | Tm (°C) |
|---|---|---|---|---|
| KRTAP2-3 | CTCCACCTTGTCCTCCCTGA | GGCAGGGCTCGCAGATG | 155 | 61 |
| FOSL1 | GAAGGCCTTGTGAACAGGAG | CTTCCAGCACCAGCTCTAGG | 111 | 60 |
| MMP1 | CCAAGGTCTCTGAGGGTCAA | CTGGTTGAAAAGCATGAGCA | 114 | 60 |
| MYPN | AATGAGACCATCCCTTGCAC | TGGCTGACAACGTGTACCAT | 121 | 60 |
| ENSG00000231826.1 | CCAGCTTTGTCCTGACCTTC | GTTGCTGCCAAACTGCTACA | 121 | 60 |
| ALPP | AGAATCTGGTGCAGGAATGG | AGGCTCAAAGAGACCCATGA | 122 | 60 |
| ENSG00000237862.1 | CATGGCCTCCTGATGAAGAT | AAGCAGGTTGGAAGTCAGGA | 119 | 60 |
| LRRC15 | TCGACCACCTGGTAGGACTC | TTCTCATACAGCCGGAGGAC | 115 | 60 |
| TMEM40 | AGATGGGAAGGCTGGACTCT | TTGCTCTCTGAGGAGGAGGA | 120 | 60 |
| ALPL | GACAAGAAGCCCTTCACTGC | AGACTGCGCCTGGTAGTTGT | 120 | 60 |
| TMEM200A | GCTATGGCCGTTCTTGGATA | AAAGAAGCGAACCACCACAC | 120 | 60 |
| LCE2A | CAGCAAAACCAGCAGCAGT | CCACAGCAGGAAGAGACTGG | 125 | 61 |
| SIRPB1 | CTGTGCTATGACGTCCCTGA | GTTGTTACCCGTGGGAAGTG | 114 | 60 |
| SESN3 | ATGCTTTGGCAAGCTTTGTT | GCAAGATCACAAACGCAGAA | 112 | 60 |
| PEAR1 | CCTGATCCATGACCGAGACT | CCGTACTGGAGGCAAGTCAT | 124 | 60 |
| HSD17B6 | TCTGGGGACTGGTGAACAAT | AAGGTCACCTGGATCACACC | 121 | 60 |
| ENSG00000261159.1 | GGCTGCATTTTGTCCTGTCT | TGACTGTGCTGACCAAGAGC | 127 | 60 |
| INHBA | AGACGCTGCACTTCGAGATT | GGATGGTGACTTTGGTCCTG | 120 | 60 |
| ARNT2 | GGATGAGGTGTGGAAATGCT | ACCACAGCATATTGGGCTTC | 121 | 60 |
| IGFN1 | GGGTCAGAACAGCCTATGGA | CATCTGCTGATCCCATTCCT | 120 | 60 |
| RXFP4 | TGCCTGTCAAATTCCTAGCC | CTCTCCGGGCACAGTTACTC | 120 | 60 |
The table displays the List of primers used for candidate genes after psoralen treatment. It holds the primers sequences, production size and the annealing temperature (Tm)
Fig. 1Identification and characterization of exosomes. a Representative transmission electron microscopy image of MCF-7 and MCF-7/ADR derived exosomes, showing a typical “saucer-like” morphology and a diameter of 30–100 nm (scale bar, 100 nm). b and c Analysis of exosome size indicated similar particle size distribution of exosomes secreted by MCF-7 and MCF-7/ADR (mean ± SD). d Exosome purity as assessed by western blot analysis for the expression of the exosomal marker CD63, TSG101 and endoplasmic reticulum protein calnexin. P-gp in total cellular protein and corresponding exosomes of MCF-7 and MCF-7/ADR cells were also detected
Fig. 2ADR/exo transfer chemoresistance to recipient cells. a The uptake of the fluorescently labelled Exo/ADR was evident in 90% MCF-7 cells after 12 h of incubation. No stain was revealed in the negative control condition (PBS). b Drug-resistance-related mRNA changes (MDR-1, MRP and LRP) in MCF-7 incubated with ADR/exo. ADR/exo induced a increase of MDR-1, MRP and LRP mRNA levels compared to MCF-7 and MCF-7 + S/exo cells, especially the MDR-1 (p < 0.05). c IC50 of adriamycin was determined by MTT. The results showed that MCF-7 cells after incubation with ADR/exo displayed 5.5 fold greater resistance to adriamycin than MCF-7 cells. MCF-7 + ADR/exo had greater resistance to adriamycin, p < 0.05 compared to MCF-7 cells. d Confocal micrographs showing adriamycin localization in MCF-7+ ADR/exo cells. Scale bars, 25 μm
Fig. 3Different amounts of formation and secretion of exosomes in MCF-7, MCF-7/ADR and MCF-7/ADR + psoralen cells. a Transmission electron micrographs of exosomes structures (25,000×). b Confocal images of immunostaining for exosomes CD63 expression in MCF-7/ADR and MCF-7/ADR + psoralen cells. Scale bars, 50 μm
Fig. 4A number of genes are differentially expressed in MCF-7 and MCF-7/ADR vs. MCF-7 + psoralen and MCF-7/ADR + psoralen. Ribosomal RNA-free total RNA extracts were prepared from 24 h derived from each of 3 donors and subjected to RNA-seq analysis. A heat map was generated using the significant DE genes with a P value of 0.01
Fig. 5Fold Changes of DE genes (MCF-7 and MCF-7/ADR vs. MCF-7 + psoralen and MCF-7/ADR + psoralen). The barchart displays the log2 fold changes of validated candidate genes, which showed significant differences in their expression in MCF-7 and MCF-7/ADR vs. MCF-7 + psoralen and MCF-7/ADR + psoralen, respectively. Positive values indicate an up-regulation after psoralen treatment. Negative values indicate an down-regulation fter psoralen treatment. Black bars denote values resulting from RNA-Seq analysis. Gray bars denote values resulting from RT-qPCR analysis
Relative expression level of Psoralen group over that Control group
| Gene symbol | Control | Psoralen | log2FoldChange |
|
|---|---|---|---|---|
| KRTAP2-3 | 473.4431128 | 77.96785331 | −2.602239769 | 1.55E-31 |
| FOSL1 | 11296.63679 | 5566.561955 | −1.021034857 | 3.49E-26 |
| MMP1 | 1170.248705 | 212.1662542 | −2.463548055 | 1.18E-13 |
| MYPN | 456.4454562 | 187.019253 | −1.287255674 | 1.63E-10 |
| ENSG00000231826.1 | 761.8035897 | 366.7059488 | −1.054795416 | 7.26E-08 |
| ALPP | 320.5900834 | 127.107873 | −1.334676407 | 1.22E-07 |
| ENSG00000237862.1 | 247.8975043 | 105.2724733 | −1.235615498 | 1.45E-07 |
| LRRC15 | 313.4134599 | 144.8134519 | −1.113871516 | 3.37E-07 |
| TMEM40 | 398.6759476 | 196.9516533 | −1.017375042 | 5.19E-07 |
| ALPL | 205.4467798 | 88.21207065 | −1.21971673 | 1.31E-06 |
| TMEM200A | 714.8598445 | 303.7664782 | −1.234697743 | 3.42E-06 |
| LCE2A | 455.8712616 | 224.9098164 | −1.019279833 | 8.62E-06 |
| SIRPB1 | 43.66423935 | 9.736212337 | −2.165019671 | 1.03E-05 |
| SESN3 | 73.33189937 | 163.1626044 | 1.153797628 | 1.94E-05 |
| PEAR1 | 195.9475924 | 80.66338615 | −1.280481972 | 2.38E-05 |
| HSD17B6 | 83.7271271 | 31.44521183 | −1.412854769 | 3.95E-05 |
| ENSG00000261159.1 | 17.47612762 | 1.611337899 | −3.439054581 | 6.33E-05 |
| INHBA | 92.57825197 | 34.35526917 | −1.430141936 | 6.82E-05 |
| ARNT2 | 115.3737968 | 50.98582145 | −1.17814759 | 8.87E-05 |
| IGFN1 | 87.83302938 | 31.6306287 | −1.473441332 | 1.02E-04 |
| RXFP4 | 0 | 10.4296342 | Inf | 1.26E-04 |
The table displays the results of the RNA-Seq data comparison before and after psoralen treatment. It holds the description, log2 fold change (FC) of the differentially expressed genes. Positive log2 fold changes indicate higher gene expression after psoralen treatment, while negative log2 fold changes indicate lower gene expression after psoralen treatment